University of Colorado Cancer Center

 

University of Colorado Cancer Center
J

ES-SCLC Paradigm Change Following IMpower133 and CASPIAN Trials: What Is the Role of Durvalumab in 1L Setting? How Does the Addition of Atezolizumab to CP/ET Affect Patient Outcomes?

By University of Colorado Cancer Center FEATURING Jose Pacheco
By University of Colorado Cancer Center FEATURING Jose Pacheco
629 views
August 17, 2020
0 Comments
Login to view comments. Click here to Login
Videos
55:10
University of Colorado Cancer Center

History of Cancer and Its Treatment: What Will It Take to Cure?

Feat. C. Lieu
20:06
University of Colorado Cancer Center

Frontline Treatment of ALL: Current Standards and Emergence of CAR-T

Feat. M. Schwartz
08:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "TRANSFORM Study - 3-Year Follow-Up Compar…

Feat. M. Kamdar
07:38
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - A…

Feat. M. Kamdar
39:44
University of Colorado Cancer Center

Understanding Immune Fitness and Age to Improve Breast Cancer Outcom…

Feat. S. Mcallister
44:36
University of Colorado Cancer Center

Type 2 Diabetes Risk With Endocrine Therapies for Breast Cancer

Feat. R. Scalzo
10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
13:36
University of Colorado Cancer Center

Colorectal Surgery for Lynch Syndrome

Feat. J. Vogel
15:33
University of Colorado Cancer Center

Treatment Options for Patients With Lynch Syndrome & CRC

Feat. C. Lieu
41:30
University of Colorado Cancer Center

Lynch Syndrome: The Past, the Present, and the Future

Feat. P. Lynch
46:03
University of Colorado Cancer Center

CAR NK Cells: Next Generation Cell Therapies for Cancer

Feat. K. Rezvani
14:52
University of Colorado Cancer Center

Efforts to Understand Metastatic Drivers of Acral Melanoma

Feat. V. Rebecca
22:23
University of Colorado Cancer Center

Delineating the Therapy Resistance Landscape of Acral Melanoma

Feat. V. Rebecca
07:25
Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "The Use of Rucaparib vs. Placebo Maintenanc…

Feat. B. Corr
11:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Selection of Bispecific Antibody Therapies …

Feat. M. Kamdar
07:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Re…

Feat. M. Amaya
14:59
University of Colorado Cancer Center

EGFR Exon 20 Insertion Mutations in NSCLC: Optimal and “Soon to Be O…

Feat. T. Patil
11:37
Insights from 2023 ASCO® Annual Meeting

Assessment and Decision Tools for Balancing Survival and Quality of …

Feat. E. Kessler
21:12
University of Colorado Cancer Center

Current 1L Approaches to ALK and ROS1 NSCLC

Feat. T. Patil
09:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Effect of CBM588 in Combination With Cabo…

Feat. H. Ebrahimi
05:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Updated Results for Cohort H of EV-103 Tr…

Feat. T. Flaig
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar
03:26
PrecisCa

The BRUIN Study: Pirtobrutinib in Mantle Cell Lymphoma

Feat. M. Kamdar
07:47
PrecisCa

Treatment Approach for Older Patients With Mantle Cell Lymphoma: A D…

Feat. M. Kamdar
02:52
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of …

Feat. M. Amaya
03:33
PrecisCa

Mosunetuzumab in R/R Follicular Lymphoma

Feat. M. Kamdar
02:53
PrecisCa

The POLARIX Trial: Polatuzumab With R-CHP in DLBCL

Feat. M. Kamdar
06:28
PrecisCa

Updates From the ECHELON-1 Trial Utilizing Brentuximab in Hodgkin’s …

Feat. M. Kamdar
18:33
Total Health

Sexual & Marital Dysfunction in Women With Gynecologic Cancer

Feat. S. Guntupalli
21:35
Total Health

Management of Advanced NSCLC: IO, Targeted Therapy, and Beyond

Feat. T. Patil
22:52
Total Health

Breast Cancer Genetics, Genomics, and Emerging Diagnostic Tools

Feat. R. Acharya-Leon
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
19:23
University of Colorado Cancer Center

Evolving Paradigms in the Management of Early-Stage NSCLC

Feat. T. Patil
12:42
University of Colorado Cancer Center

Management of Patients With R/R MCL

Feat. M. Kamdar
40:59
University of Colorado Cancer Center

Cancer 'Super-Survivors': ALK+ NSCLC

Feat. R. Camidge
04:56
University of Colorado Cancer Center

Liso-Cel CAR T-Cell Therapy vs. Salvage Chemo Followed by ASCT as 2L…

Feat. M. Kamdar
08:29
University of Colorado Cancer Center

Application and Development of ctDNA in Early Stage CRC

Feat. C. Lieu
07:12
i3 Health

New Opportunities in Advanced KRAS Mutation-Positive NSCLC: Biomarke…

Feat. R. Camidge, B. Sandy
11:24
University of Colorado Cancer Center

Practical Principles of Biomarker Testing in aNSCLC: FDA Approved Th…

Feat. T. Patil
15:14
University of Colorado Cancer Center

Practical Principles of Biomarker Testing in aNSCLC: Overview of Cur…

Feat. T. Patil
09:54
University of Colorado Cancer Center

Targeting mNSCLC: Alectinib & Crizotinib, Chemoimmunotherapy in …

Feat. T. Patil
06:46
University of Colorado Cancer Center

KRAS-G12V-Mutant NSCLC: Is There Any Benefit With RAF/MEK Inhibitor …

Feat. R. Camidge
14:33
University of Colorado Cancer Center

KRAS-Mutated NSCLC Update: Are We Close to a Highly-Effective Target…

Feat. J. Pacheco
20:06
University of Colorado Cancer Center

How I Treat Lung Cancer in 2020: Major Risk Factors & Death Rate…

Feat. T. Patil
10:45
University of Colorado Cancer Center

How I Treat Early NSCLC in 2020: How Critical Is Lymph Node Determin…

Feat. T. Patil
09:29
University of Colorado Cancer Center

mNSCLC Treatment: How Critical Is Molecular Profiling for Targeted T…

Feat. T. Patil
15:28
University of Colorado Cancer Center

ES-SCLC Paradigm Change Following IMpower133 and CASPIAN Trials: Wha…

Feat. J. Pacheco
25:36
University of Colorado Cancer Center

Brigatinib vs Crizotinib in Advanced ALK+ NSCLC: A Glimpse Into the …

Feat. R. Camidge